| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (NCT05350787) | Zhejiang University | 2022-03-18 |
| Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL (NCT05350852) | Zhejiang University | 2022-03-18 |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL (NCT04781634) | Chongqing Precision Biotech Co., Ltd | 2021-03-07 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (NCT04512716) | Memorial Sloan Kettering Cancer Center | 2021-02-02 |
| Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04792593) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-12-03 |
| Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia (NCT04723901) | Shenzhen University General Hospital | 2020-10-20 |
| Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia (NCT04546893) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-09-01 |
| Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04546906) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-09-01 |
| Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (NCT04499573) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2020-07-27 |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL (NCT03751709) | Cedars-Sinai Medical Center | 2020-02-14 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (NCT04088890) | Matthew Frank | 2019-09-12 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393) | National Cancer Institute (NCI) | 2018-03-26 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| Multi-centric Study (NCT01219816) | Nantes University Hospital | 2010-11-01 |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) (NCT01209286) | Amgen Research (Munich) GmbH | 2010-10-01 |
| Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma (NCT01290120) | Northern Italy Leukemia Group | 2002-11-01 |